<i>MGMT</i> promoter methylation and <i>IDH1</i> mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme.

Agnieszka Woźniak, Paul M. Clément, Hilko Ardon et al.|Journal of Clinical Oncology|2010

Cited by 1